Early-stage startup valuation is mostly made up.
I mean that with less cynicism than it sounds. A $10 million pre-revenue company and a $30 million pre-revenue company, in the same sector with the same team quality, are both being valued on almost entirely the same inputs: narrative, market timing, and comparable recent rounds. The extra 20 million does not come from a spreadsheet. It comes from conviction, competition, and negotiation.
That does not mean valuation methods are useless. They matter. But most founders and new investors misunderstand which methods matter at which stages, and they spend disproportionate time on the ones that produce the least signal.
This guide is what I wish someone had shown me: the real methods, what they actually tell you, and where the number that ends up on the term sheet actually comes from.
What Valuation Is and Is Not
Valuation, in venture, is the pre-money value of the company assigned at a financing round. Pre-money plus the amount raised equals post-money. Your ownership post-round is the check divided by post-money.
That is the math. The confusion is that people treat this number as a statement about the company's current worth. It is not. It is a statement about what one group of investors is willing to pay, at this moment, for this amount of ownership, given the alternatives available to them.
Valuation at early stages is a market-clearing price, not an intrinsic value. Everything below is how that price gets set.
A useful mental model: public market valuation is primarily about cash flow projections anchored to real financials. Early-stage private valuation is primarily about narrative, market comparables, and investor competition, with financials playing a secondary role until growth-stage rounds.
The Methods That Actually Drive Early-Stage Prices
At pre-seed and seed, three methods dominate. Everything else is commentary.
1. Recent Comparable Transactions
This is the single biggest input for early-stage valuation. Investors look at recent rounds in the same sector, at the same stage, with roughly comparable teams and traction, and anchor their offer price to that range.
If a seed round in B2B SaaS infrastructure typically clears at $8M to $15M pre-money in the current market, a specific deal has to justify being above or below that band. The justification is story, not spreadsheet.
What drives comparables:
- Sector heat. Hot sectors trade at premium multiples. When AI infrastructure is in vogue, valuations inflate across the sector, often by 50% or more.
- Geography. Silicon Valley comps are typically 20% to 40% higher than comparable companies in other regions. Fair or not.
- Vintage. 2021 seed comps were dramatically higher than 2023 comps. Comparables from the wrong vintage mislead more than they help.
- Stage definition. "Seed" has expanded. Some modern seed rounds look like 2016 Series As. Comparables have to match actual stage, not label.
Brevoir sector funding dashboard with recent comparable rounds
Add screenshot here
Current round data→ is how serious investors calibrate their offers. Without visibility into recent comps in the right sector and geography, you are either overpaying or underbidding relative to the market.
2. Ownership-Target Math
Funds have ownership targets. A typical seed fund might need 8% to 15% of a company at entry to hit their portfolio construction model. A pre-seed fund might need 5% to 10%.
When a fund offers a valuation, they are not starting from the number. They are starting from the check size they can write and the ownership they need. If they want 10% and can write $2M, they are offering an $18M pre-money ($20M post). If they want 10% and can only write $1M, they are offering $9M pre-money.
This is why different funds offer different valuations on the same deal. It is not that one believes the company is worth more. It is that their fund math produces a different number.
When a fund's offer seems disconnected from your expectations, it is often because their fund size, check size, and ownership target produce a specific valuation range regardless of the company's fundamental merits. Understanding the fund's math is more useful than arguing the valuation.
3. Berkus Method and Scorecard Variants
For very early pre-revenue companies, some angels and angel groups use structured heuristics like the Berkus Method or the Scorecard Method. These assign dollar values to categories like sound idea, prototype quality, management team, strategic relationships, and early traction, then sum to a pre-money estimate.
In practice, these methods are most useful for disciplining angel thinking, not for setting market prices. Institutional VCs rarely use them. They are a way of saying "I think this team is in the 7 out of 10 range, so around this much" more than a calculation.
Worth knowing. Not worth fetishizing.
The Methods That Matter Later
At Series A and beyond, additional methods come into play because there is actual business data to work with.
Revenue Multiples
Once a company has real revenue, comparable revenue multiples become meaningful. A B2B SaaS company doing $3M ARR growing 200% year-over-year in the current market might trade at 15x to 25x forward ARR. That produces a concrete pre-money range.
Key variables:
- Growth rate. A company growing 200% trades at very different multiples than one growing 80%.
- Net revenue retention. Retention above 130% materially increases multiples. Below 100% usually caps them.
- Gross margin. Software-like economics trade at higher multiples than service-heavy businesses.
- Capital efficiency. Revenue per dollar raised matters more than it used to. Burn-heavy growth is penalized in the current market.
Discounted Cash Flow (Mostly Theater)
DCF analysis gets a lot of textbook attention and almost no real weight at early stage. Projecting free cash flows 10 years out for a pre-revenue company is fiction, and everyone at the table knows it.
DCF becomes meaningful at growth stage, when there is enough revenue and business model clarity to project reasonable cash flows. Before that, it is a spreadsheet exercise that produces whatever number the modeler wants to see.
Comparable Public Company Analysis
At growth stage and late stage, the trading multiples of comparable public companies become an anchor. A growth-stage B2B SaaS company is valued partly by reference to the public multiples of Snowflake, Datadog, MongoDB, etc., discounted for private market illiquidity and company-specific risk.
Not relevant at seed. Highly relevant at Series C and beyond.
How the Final Number Actually Gets Set
Given all the methods, what actually happens in the room?
The honest version, based on hundreds of deals I have watched or participated in:
- The lead investor anchors. They propose a valuation based primarily on recent comparables and their fund's ownership math, adjusted for their view of the company's quality within the comp set.
- The founder pushes back or accepts. If the founder has other offers, they use them as leverage. If they do not, the lead's number usually sticks with minor adjustments.
- Investor competition sets the ceiling. The most important single input to final valuation at early stage is how many credible investors are competing for the round. A hot round with three term sheets trades 30% to 100% higher than a cold round with one.
- Market conditions set the floor and ceiling. In a hot market, valuations inflate across the board. In a cold market, even the best companies accept lower prices. The macro is 40% of the outcome at any given moment.
Founders underestimate how much their valuation is determined by process quality rather than company quality. Running a clean process with multiple parallel investors in diligence typically produces a 20% to 50% higher valuation than a serial one-at-a-time process, for the same company.
The "Right" Valuation for Founders
I get asked constantly what the "right" valuation is. The honest answer is: the highest number you can get from investors you actually want on your cap table, provided it does not create problems for the next round.
Too Low
Leaving meaningful capital on the table. You end up with more dilution than necessary for the capital raised. Over several rounds, this compounds painfully.
Too High
Creates two risks. First, if you do not grow into the valuation, the next round is a down round, which is damaging to morale, team, and follow-on signaling. Second, at a high valuation, you effectively pre-commit to a specific growth path, and missing it is punished disproportionately.
The practical rule: take the highest valuation where you can confidently hit the milestones that justify a 2x to 3x markup at the next round in 18 to 24 months. Higher than that, and you are borrowing against future performance you may not deliver.
The Friendly Round Trap
When friends, family, or early angels push for a very high valuation "because I believe in you," take it with caution. High friends-and-family valuations poison later rounds. Institutional investors see a $10M pre-money friends-and-family round and either pass or mark you down internally, which is sometimes worse than passing.
Keep early rounds pragmatic. Save the premium valuations for later rounds where institutional investors are setting the market.
The "Right" Valuation for Investors
For investors, the equation is different. You are not optimizing against dilution. You are optimizing against expected return.
The key question: at this entry price, what is the probability-weighted outcome?
Consider a seed check at $15M post-money. For this to be a good investment, the company has to realistically be worth, say, $500M to $1B at exit, and the probability of that outcome needs to be high enough to justify the expected value.
If an otherwise identical company is available at $10M post-money, the same exit produces 1.5x the return. That 50% improvement matters enormously over a portfolio of 30 checks.
A common mistake among new angels: treating valuation as a minor negotiable rather than a primary driver of returns. Over a portfolio, entry valuation is one of the two or three largest factors in final performance, along with company selection and ownership maintained through follow-on.
What to Ignore
A few things that get discussed in valuation conversations that do not actually matter much at early stage:
- TAM-based valuation. "The market is $50 billion, and we only need 2% of it." This is a slide, not a method. No one prices rounds based on it.
- Cost-to-rebuild valuation. How much it would cost to rebuild the product from scratch. Interesting trivia, irrelevant to pricing.
- Founder salary forgone. The opportunity cost of founders not taking market salaries. Fair point, not a valuation driver.
- Hype around recent AI deals. Valuation anchors should come from your sector, not from the headline numbers in unrelated sectors.
If a valuation conversation is anchored on any of these, it is probably being driven by narrative rather than analysis.
The Uncomfortable Conclusion
Valuation at early stage is a negotiation informed by imperfect comparables, constrained by fund math, calibrated by market conditions, and resolved by competitive dynamics. It is not a calculation.
The best founders and investors I know treat it that way. They spend their time on the inputs that actually move the number (comparables, process quality, investor competition) rather than building elaborate spreadsheets that give them the illusion of precision.
The most useful tool for getting valuation right is real-time visibility into what is actually clearing in your sector, at your stage, in your geography, right now. Without that, you are negotiating in the dark.
If you are a founder, know your comps before you walk into a pitch meeting. If you are an investor, know your sector's pricing so you do not overpay in hot markets or miss good deals by lowballing in cold ones. Both sides win when valuation is grounded in current market reality instead of three-year-old assumptions or generic industry averages.
That real-time sector comp visibility is part of what Brevoir→ exists to deliver. Funding velocity, round sizes, sector momentum, and comparable transactions→ across your target sectors and geographies, updated continuously, so pricing conversations are grounded in data instead of vibes.
Written by
Nabil AbuhadbaCEO and founder of Brevoir. Building the intelligence infrastructure for private markets. Previously obsessing over data, startups, and the future of investing.
Brevoir Signal
Get the weekly signal across private markets
Twice a week. Sector momentum, the deals that closed, the strongest fundraising signal, and the contrarian read your inbox is missing. Free.
Related Posts
Pre-Seed vs Seed vs Series A: What Investors Need to Know
A practical breakdown of the three earliest startup funding stages. How they differ in check sizes, valuations, milestones, investor expectations, and what each stage really means in 2026.
The Complete Guide to Angel Investing for Beginners
A beginner's guide to angel investing that does not pretend it is easy. How to start, how much to commit, how to source, evaluate, and avoid the mistakes that sink most new angels.
How VCs Actually Evaluate Startups (Inside the Process)
A look inside how venture capitalists really evaluate startups, from first meeting to term sheet. The criteria, the framework, and the internal dynamics founders rarely see.